Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (51-60 of 151) with videos related to

Pageof 16
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2024
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysisDing-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, et al.
The Journal of Urology|August 23, 2017
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN TrialD Robert Siemens, Laurence Klotz, Axel Heidenreich, et al.
The Lancet. Oncology|January 18, 2016
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 studyNeal D Shore, Simon Chowdhury, Arnauld Villers, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 4, 2018
Imaging α<sub>v</sub>β<sub>3</sub> integrin expression in skeletal metastases with <sup>99m</sup>Tc-maraciclatide single-photon emission computed tomography: detection and therapy response assessmentGary J R Cook, Gurdip K Azad, Benjamin P Taylor, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2022
Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN studyHuybrecht T'jollyn, Oliver Ackaert, Caly Chien, et al.
Acta Oncologica (Stockholm, Sweden)|September 5, 2012
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminomaLaura Tookman, Sukaina Rashid, Athena Matakidou, et al.
Journal of Hematology & Oncology|October 27, 2015
Complexity of FGFR signalling in metastatic urothelial cancerAlejo Rodriguez-Vida, Matilde Saggese, Simon Hughes, et al.
Advances in Therapy|December 9, 2019
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate CancerSimon Chowdhury, Stéphane Oudard, Hiroji Uemura, et al.
Advances in Therapy|December 9, 2019
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate CancerSimon Chowdhury, Stéphane Oudard, Hiroji Uemura, et al.
European Urology|September 18, 2017
Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial CancerBernadett Szabados, Nick van Dijk, Yen Zhi Tang, et al.
Pageof 16

Showing results (51-60 of 151) with videos related to

Sort By:
Pageof 16
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2024
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysisDing-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, et al.
The Journal of Urology|August 23, 2017
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN TrialD Robert Siemens, Laurence Klotz, Axel Heidenreich, et al.
The Lancet. Oncology|January 18, 2016
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 studyNeal D Shore, Simon Chowdhury, Arnauld Villers, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 4, 2018
Imaging α<sub>v</sub>β<sub>3</sub> integrin expression in skeletal metastases with <sup>99m</sup>Tc-maraciclatide single-photon emission computed tomography: detection and therapy response assessmentGary J R Cook, Gurdip K Azad, Benjamin P Taylor, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2022
Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN studyHuybrecht T'jollyn, Oliver Ackaert, Caly Chien, et al.
Acta Oncologica (Stockholm, Sweden)|September 5, 2012
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminomaLaura Tookman, Sukaina Rashid, Athena Matakidou, et al.
Journal of Hematology & Oncology|October 27, 2015
Complexity of FGFR signalling in metastatic urothelial cancerAlejo Rodriguez-Vida, Matilde Saggese, Simon Hughes, et al.
Advances in Therapy|December 9, 2019
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate CancerSimon Chowdhury, Stéphane Oudard, Hiroji Uemura, et al.
Advances in Therapy|December 9, 2019
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate CancerSimon Chowdhury, Stéphane Oudard, Hiroji Uemura, et al.
European Urology|September 18, 2017
Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial CancerBernadett Szabados, Nick van Dijk, Yen Zhi Tang, et al.
Pageof 16